Susan McGowan, 58, took just two injections before her death in September after the new generation of drugs were hailed as an ...

The death of a Scots nurse has been linked to an approved weight loss injection which is available on NHS. Susan McGowan, ...

Mounjaro explained as Adam Lambert speaks out on Instagram live about his drastic weight loss and why he stopped taking ...

你是否感到减肥总是难以达成目标？现在，有一个新的希望正在香港浮现！10月28日，礼来公司宣布，其减肥药物Mounjaro（成分为Tirzepatide）已获得香港特区政府的销售批准，这一消息无疑引起了大众的广泛关注。对于那些在体重管理和2型糖尿病方面需要帮助的人来说，这款新药物可能会成为实现健康目标的一种有效选择。 在现代社会，肥胖和糖尿病的患病率不断上升，许多人为此感到苦恼。例如，调查显示，全球 ...

A SCOTS nurse is thought to be the first person to die in the UK after taking a weight loss injection recently approved by the NHS. Susan McGowan, 58, passed away on September 4 after taking two ...

A nurse’s death has been linked to a weight loss drug which is approved for use on the NHS. Susan McGowan, 58, died on September 4 and had recently taken two doses of the weight loss jab Mounjaro. The ...

As the battle against obesity and diabetes heats up, two new superstars are entering the ring in Spain - Mounjaro (also known ...

财报“爆雷”、行业巨头股价跌破关键点位，“炙手可热”的减肥药也要面临需求危机了？受热门减肥药Zepbound和Mounjaro销售不佳影响，礼来Q3营收利润皆不及预期，公司同时下调全年财务指引。受此影响，公司股价周三盘前一度大跌12%，全天收跌6%， ...

近年来，减肥药市场迎来了前所未有的发展热潮，尤其是礼来的热门产品Zepbound和Mounjaro更是其中的佼佼者。然而，最近的市场表现却令人担忧——礼来因销售业绩未达预期而遭遇大幅下跌，股价一度跌幅超过12%。这一现象是否意味着减肥药市场正在遭遇“撞墙”？ 一、引人注目的市场现象 减肥药作为医药领域的“摇钱树”，近年来吸引了大量投资者和消费者的关注。根据礼来的最新财报，尽管减肥药的整体需求依然存 ...

智通财经获悉，礼来公司 (LLY.US)预计最早将于今年年底开始在香港销售其广受欢迎的减肥药，这可能使其成为首个在中国地区上市的减肥药。该公司在一份声明中表示，该公司已获得香港政府的批准，可以在一种名为Kwikpen (预充式注射笔)的设备中销售其品牌名为Mounjaro的Tirzepatide注射剂注射剂，用于长期体重管理和2型糖尿病。

The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...